CAS 121808-62-6
:Pidotimod
Descripción:
Pidotimod es un agente inmunomodulador sintético utilizado principalmente en el tratamiento de infecciones respiratorias recurrentes, particularmente en niños. Se caracteriza por su capacidad para mejorar la respuesta inmune, especialmente al estimular la actividad de los linfocitos T y promover la producción de citoquinas. Pidotimod es conocido por su baja toxicidad y perfil de seguridad favorable, lo que lo hace adecuado para su uso a largo plazo. La sustancia se administra típicamente por vía oral y se absorbe bien en el tracto gastrointestinal. Su mecanismo de acción implica la modulación tanto de la inmunidad innata como de la adaptativa, lo que ayuda a mejorar la defensa del cuerpo contra patógenos. Pidotimod también ha sido estudiado por sus posibles beneficios en diversas condiciones alérgicas y autoinmunitarias. Como entidad química, se clasifica como una pequeña molécula con una estructura molecular específica que contribuye a su actividad biológica. En general, Pidotimod representa una opción terapéutica valiosa para mejorar la función inmune y reducir la frecuencia de infecciones.
Fórmula:C9H12N2O4S
InChI:InChI=1S/C9H12N2O4S/c12-7-2-1-5(10-7)8(13)11-4-16-3-6(11)9(14)15/h5-6H,1-4H2,(H,10,12)(H,14,15)/t5-,6-/m0/s1
Clave InChI:InChIKey=UUTKICFRNVKFRG-WDSKDSINSA-N
SMILES:C(=O)(N1[C@H](C(O)=O)CSC1)[C@H]2NC(=O)CC2
Sinónimos:- (4R)-3-[[(2S)-5-Oxo-2-pyrrolidinyl]carbonyl]-4-Thiazolidinecarboxylic acid
- 4-Thiazolidinecarboxylic acid, 3-[(5-oxo-2-pyrrolidinyl)carbonyl]-, [R-(R*,S*)]-
- 4-Thiazolidinecarboxylic acid, 3-[[(2S)-5-oxo-2-pyrrolidinyl]carbonyl]-, (4R)-
- Adimod
- Axil (pharmaceutical)
- Onaka
- Pidotimond
- Pigitil
- Polimod
- Pidotimod
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Encontrado 11 productos.
(4R)-3-{[(2S)-5-oxopyrrolidin-2-yl]carbonyl}-1,3-thiazolidine-4-carboxylic acid
CAS:Fórmula:C9H12N2O4SPureza:98%Forma y color:SolidPeso molecular:244.2676Pidotimod
CAS:<p>Pidotimod is a synthetic dipeptide with immunomodulatory properties.</p>Fórmula:C9H12N2O4SPureza:97.56% - 99.74%Forma y color:Almost White To White Crystalline PowderPeso molecular:244.27(R)-3-((S)-5-Oxopyrrolidine-2-Carbonyl)Thiazolidine-4-Carboxylic Acid
CAS:(R)-3-((S)-5-Oxopyrrolidine-2-Carbonyl)Thiazolidine-4-Carboxylic AcidPureza:98%Peso molecular:244.27g/molPidotimod
CAS:Fórmula:C9H12N2O4SPureza:>98.0%(T)(HPLC)Forma y color:White to Almost white powder to crystalPeso molecular:244.27Pidotimod
CAS:Producto controlado<p>Applications Immunostimulant used in patients with cell-mediated immunodepression.<br>References Gu, C., et al.: Pharm. Res., 25, 979 (2008), Fliri, A., et al.: J. Med. Chem., 52, 8038 (2009), Giagulli, C., et al.: Int. Immunopharmacol., 9, 1366 (2009),<br></p>Fórmula:C9H12N2O4SForma y color:NeatPeso molecular:244.27Pidotimod
CAS:<p>Pidotimod is a small molecule (dipeptide) that acts as immunomodulator. It activates the immune system by binding to Toll-like receptor (TLR) 4 and TLR2 and it is involved in the regulation of TLRs signaling pathways. Pidotimod has chemokine activity on CXC chemokine receptor 3 (CXCR3) that triggers monocyte adhesion and migration by activation of tyrosine phosphorylation-based cell signaling. Recent studies showed that pidotimod can be used to treat acute respiratory tract infections (RTIs) and its pharmacokinetic studies has shown its ability to boost the immunoresponse and favouring the increase in the level of immunoglobulins (IgA, IgM, IgG) and T-lymphocytes (CD3+, CD4+). Pidotimod also exhibits anti-inflammatory properties by inhibiting the production of pro-inflammatory molecules such as IL-6 and TNF-α, which are linked to autoimmune diseases</p>Fórmula:C9H12N2O4SPureza:Min 98%Forma y color:White PowderPeso molecular:244.27 g/molPidotimod - Bio-X ™
CAS:<p>Pidotimod is a small molecule (dipeptide) that acts as immunomodulator. It activates the immune system by binding to Toll-like receptor (TLR) 4 and TLR2 and it is involved in the regulation of TLRs signaling pathways. Pidotimod has chemokine activity on CXC chemokine receptor 3 (CXCR3) that triggers monocyte adhesion and migration by activation of tyrosine phosphorylation-based cell signaling. Recent studies showed that pidotimod can be used to treat acute respiratory tract infections (RTIs) and its pharmacokinetic studies has shown its ability to boost the immunoresponse and favouring the increase in the level of immunoglobulins (IgA, IgM, IgG) and T-lymphocytes (CD3+, CD4+). Pidotimod also exhibits anti-inflammatory properties by inhibiting the production of pro-inflammatory molecules such as IL-6 and TNF-α, which are linked to autoimmune diseases.</p>Fórmula:C9H12N2O4SForma y color:PowderPeso molecular:244.27 g/mol(R)-3-((S)-5-Oxopyrrolidine-2-carbonyl)thiazolidine-4-carboxylic acid
CAS:Fórmula:C9H12N2O4SPureza:98%Forma y color:SolidPeso molecular:244.27








